Bevacizumabbal szerzett tapasztalat nem kissejtes tüdöräkban

Translated title of the contribution: Experience with bevacizumab in non-small cell lung cancer

Lilla Tamási, László Agócs, Pál Magyar

Research output: Contribution to journalArticle


Bevacizumab, a recombinant anti-vascular endothelial growth factor antibody, is the antiangiogenic drug used at advanced stage of non-small cell lung cancer. It is the only antiangiogenic therapy up till know available with reimbursement in Hungary. It is indicated in the first-line, platinum-based treatment of advanced stage non-squamous non- small cell lung cancer, and used together with chemotherapy. CASE REPORT- In this case report we present the case of a patient with advanced stage pulmonary adenocarcinoma, with a progression- free survival of more than one year with bevaci- zumab-docetaxel-cisplatine therapy. CONCLUSION - Bevacizumab given together with combination chemotherapy is effective in advanced lung adenocarcinoma.

Translated title of the contributionExperience with bevacizumab in non-small cell lung cancer
Original languageHungarian
Pages (from-to)509-512
Number of pages4
JournalLege Artis Medicinae
Issue number8-9
Publication statusPublished - Oct 12 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Experience with bevacizumab in non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this